MEX3A

Across TCGA pan-cancer cohorts, MEX3A Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MEX3A data layer compared with 30 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MEX3A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MEX3A expression acts as an unfavorable survival marker.

ESCA, READ, and PRAD are the cancer types where MEX3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.179	0.531	.001	18	view →
READ	DFS	Median	III,IV	0.182	0.745	.007	15	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	All	0.141	0.564	.010	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LUSC	OS	Median	All	0.196	0.724	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MEX3A–ESCA (DFS)

Open the ESCA breakdown →